Strategies for Phenotypic Drug Discovery Programs Using High-Content Imaging

Phenotypic screening has become a key strategy for identifying new therapeutics due to the ability to perform screens without knowing the target of interest. Phenotypic screens can be used to identify agents that reverse a disease state or to identify mechanisms of action of compounds in libraries. Strategies using multiplexed imaging approaches allow for high-content screening and analysis, thus increasing the depth of knowledge obtainable in a screen. Recent advantages in automation, miniaturization, imaging and analysis have dramatically increased the size of libraries and complexity of disease states which can be examined.

In this webinar, experts will discuss the current state of high-content screening for drug discovery. Discussion topics will include:

• Considerations for setting up phenotypic screens
• Resources necessary for cell biology, imaging and data analysis
• Current status of cell painting for drug discovery and future directions

Speakers

Matthew Betzenhauser, PhD, Senior Research Scientist III, Curia

Matthew Betzenhauser, PhD is the team lead for the Cell Based Assay Technology team at Curia, formerly AMRI in Buffalo, NY. The Cell Based Assay Technology team leverages high content imaging and analysis in support of client programs to develop new models of disease and test novel therapeutics in oncology, immunology, neurobiology and other major human systems. Matthew earned his Ph.D. in Pharmacology at the University of Rochester where he used imaging-based assays to study calcium signaling pathways in cells. 

Message Presenter

Clark Driscoll, MS, Research Scientist III, Curia

Clark Driscoll, MS is a Research Scientist II who started his career at Curia more than five years ago, after completing his Master’s thesis. Clark has worked to develop novel live cell and fixed cell-based imaging assays that have been used in high-throughput screening campaigns.

Message Presenter

George Opoku-Kusi, PhD, Senior Research Scientist, Curia

George Opoku-Kusi, PhD is a Research Scientist III who started at Curia in 2020 after completing doctoral and postdoctoral studies at the University of South Dakota where he developed novel imaging-based assays for drug discovery in primary human immune cells.

Message Presenter